$GERN

Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO)

Analysts commented on Geron (GERN) and Fair Isaac (FICO). H.C. Wainwright maintained a Hold rating on GERN with a $1.50 target, while Wells Fargo reiterated a Buy on FICO with a $1350 target. GERN has a Strong Buy consensus and 233.1% upside, FICO has a Moderate Buy consensus and 56.3% upside.

Original reporting
Published Sep 23, 2026, 10:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Analysts Offer Insights on NA Companies: Geron (GERN) and Fair Isaac (FICO) — source image
Decision brief

The 30-second read

$GERNNeutralLow
01

Why it matters

Analyst rating reiterations provide modest guidance but lack fresh material; limited trading impetus.

02

Market read

Analyst commentary offers slight directional bias but no actionable catalyst.

03

What to watch

Absence of earnings or news means price targets rely on assumptions rather than new data.

Relevance 4/10Novelty 2/10Timing: today

Background

The article aggregates analyst opinions on Geron and Fair Isaac without reporting new corporate events.

Company-level read

Ticker impact

$GERNNeutralMedium confidence
Context

Analyst maintained Hold rating and cited price target of $1.50, no new corporate event.

Expected impact

Limited impact; price may stay range-bound.

Evidence & confidence

Rating unchanged and target modestly above current price; unlikely to trigger large moves.

$FICOBullishMedium confidence
Context

Analyst reiterated Buy rating and set $1,350 target, no new company action disclosed.

Expected impact

Potential modest upside if investors follow target.

Evidence & confidence

Upward target may attract interest but lacks fresh catalyst.

Market effects

Both firms are in niche finance/healthcare sectors; analyst coverage may slightly influence sector sentiment.

North American market focus; minimal broader regional effect.

Limited global relevance.

Counterpoint

Ratings unchanged may suggest stagnation; investors could wait for a catalyst.

Key entities

  • Geron

    Biotech firm GERN

  • Fair Isaac

    Analytics firm FICO

Related articles

$FICOMed

FICO announces layoffs, management restructuring

FICO announced layoffs and management restructuring amid competition from VantageScore 4.0, which is being adopted by lenders like Rocket Mortgage and UWM. FHFA allows Fannie Mae and Freddie Mac lenders to use either FICO or VantageScore. FICO's Q3 2026 net income was $237.2M, with total revenues of $674.2M, driven by mortgage demand for its scores.

$FICOMed

Does A 15% Job Cut Materially Alter Fair Isaac's Margin Outlook?

Fair Isaac (FICO) announced a 15% workforce reduction on October 6, 2026, to simplify operations and integrate AI. The move targets its slower-growing Software business, which generated $0.8B in fiscal 2025. FICO's operating margin is at a 10-year high of 52.1%. The company expects to report fiscal Q4 2026 results around November 3, 2026, which may include savings figures.

$FICOMed

FICO Is Cutting 15% of Its Workforce After Losing More Than Half Its Value

Fair Isaac (FICO) is cutting 15% of its workforce, citing restructuring and AI-driven development. The move follows a 58% stock decline this year, driven by regulatory changes ending FICO's exclusive mortgage pricing grid status. Q3 2026 revenue rose 26%, but future earnings may be impacted by lower mortgage pricing. Bank of America downgraded FICO to Neutral, citing valuation concerns.